317 results on '"Durán, Ignacio"'
Search Results
2. SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023)
3. Criteria and indicators to evaluate quality of care in genitourinary tumour boards
4. Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution
5. Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor
6. Biocompatible surface functionalization architecture for a diamond quantum sensor
7. RENO Study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain
8. Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy
9. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial
10. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): “Real World” Experience
11. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
12. Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
13. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
14. Explainable GNN-Derived Structure-Property Relationships in Interstitial-Alloy Materials
15. Looking for integral references for the fission cross sections in actinides above 1 MeV
16. Experimental setup of the 239Pu neutron capture and fission cross-section measurements at n_TOF, CERN
17. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma
18. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
19. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
20. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
21. Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management
22. Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain
23. Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin
24. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
25. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
26. Pharmaceutical cost savings from the treatment of oncology patients in clinical trials
27. Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma
28. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors
29. Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial
30. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
31. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
32. Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis
33. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)
34. Measurement of the 235U(n,f) cross section relative to the 10B(n,α) reaction with Micromegas detectors at the CERN n_TOF facility: First results
35. Immunotherapy and New Combinations in Muscle-Invasive Bladder Cancer
36. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
37. From Non-Magnetic to Magnetic: A First-Principles Study of the Emergence of Magnetism in 2D (Nb1–xTix)4C3MXenes
38. Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution
39. Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group
40. Neuroendocrine Carcinoma
41. Biomarkers of response to PD-1/PD-L1 inhibition
42. Targeted Therapies in Kidney Cancer
43. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
44. Transmission and reflection of acoustic and entropy waves through a stator–rotor stage
45. Search for new fission modes in light systems around Z=60: The cerium case
46. From Non-Magnetic to Magnetic: A First-Principles Study of the Emergence of Magnetism in 2D (Nb1–xTix)4C3 MXenes.
47. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
48. Measurement of the <math><mrow><mmultiscripts><mi mathvariant='normal'>N</mi><mprescripts/><none/><mn>14</mn></mmultiscripts><mo>(</mo><mi>n</mi><mo>,</mo><mi>p</mi><mo>)</mo><mmultiscripts><mi mathvariant='normal'>C</mi><mprescripts/><none/><mn>14</mn></mmultiscripts></mrow></math> cross section at the CERN n_TOF facility from subthermal energy to 800 keV
49. Simulation and modelling of the waves transmission and generation in a stator blade row in a combustion-noise framework
50. Neuroendocrine Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.